The effect of needle length and skin to deltoid muscle distance in adults receiving an mRNA COVID-19 vaccine.
COVID-19
Deltoid muscle
Immunisation
Intramuscular injection
Needle length
Vaccination
Journal
Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899
Informations de publication
Date de publication:
05 08 2022
05 08 2022
Historique:
received:
23
03
2022
revised:
22
06
2022
accepted:
23
06
2022
pubmed:
7
7
2022
medline:
17
8
2022
entrez:
6
7
2022
Statut:
ppublish
Résumé
The mRNA COVID vaccines are only licensed for intramuscular injection but it is unclear whether successful intramuscular administration is required for immunogenicity. In this observational study, eligible adults receiving their first Comirnaty Participants (n = 402) had a mean age of 34.7 years, BMI 29.1 kg/m A 25 mm needle length is likely to be inadequate to ensure vaccine deposition within the deltoid muscle in a small proportion of adults. Vaccine-induced spike antibody titres were comparable in those vaccinated with a needle of sufficient versus insufficient length suggesting deltoid muscle deposition may not be required for an adequate antibody response to mRNA vaccines.
Sections du résumé
BACKGROUND
The mRNA COVID vaccines are only licensed for intramuscular injection but it is unclear whether successful intramuscular administration is required for immunogenicity.
METHODS
In this observational study, eligible adults receiving their first Comirnaty
RESULTS
Participants (n = 402) had a mean age of 34.7 years, BMI 29.1 kg/m
CONCLUSIONS
A 25 mm needle length is likely to be inadequate to ensure vaccine deposition within the deltoid muscle in a small proportion of adults. Vaccine-induced spike antibody titres were comparable in those vaccinated with a needle of sufficient versus insufficient length suggesting deltoid muscle deposition may not be required for an adequate antibody response to mRNA vaccines.
Identifiants
pubmed: 35792021
pii: S0264-410X(22)00839-8
doi: 10.1016/j.vaccine.2022.06.070
pmc: PMC9239984
pii:
doi:
Substances chimiques
Antibodies, Viral
0
COVID-19 Vaccines
0
RNA, Messenger
0
Vaccines
0
BNT162 Vaccine
N38TVC63NU
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
4827-4834Informations de copyright
Copyright © 2022 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Cell Rep Med. 2022 Feb 25;3(3):100562
pubmed: 35474748
Appl Nurs Res. 2013 Nov;26(4):e1-4
pubmed: 24156877
Vaccine. 2006 Feb 13;24(7):937-40
pubmed: 16191454
Clin Microbiol Infect. 2021 Dec;27(12):1861.e1-1861.e5
pubmed: 34375755
Nat Rev Drug Discov. 2021 Nov;20(11):817-838
pubmed: 34433919
Arthritis Rheum. 2003 Apr 15;49(2):156-63
pubmed: 12687505
Vaccine. 2007 Jun 15;25(25):4767-74
pubmed: 17512098
Cells. 2021 Jul 31;10(8):
pubmed: 34440721
Hum Vaccin Immunother. 2021 May 4;17(5):1329-1341
pubmed: 32991241
Clin Transl Immunology. 2021 Mar 14;10(3):e1261
pubmed: 33747511
JAMA. 1997 Jun 4;277(21):1709-11
pubmed: 9169899
BMJ. 2000 Nov 18;321(7271):1237-8
pubmed: 11082069
Vaccines (Basel). 2021 Aug 03;9(8):
pubmed: 34451973
N Engl J Med. 2021 Dec 9;385(24):e84
pubmed: 34614326
Obesity (Silver Spring). 2022 Mar;30(3):606-613
pubmed: 34850576
J Ultrasound Med. 2022 May;41(5):1295-1297
pubmed: 34403167
Nature. 2020 Aug;584(7821):430-436
pubmed: 32640463
Pediatrics. 2010 Mar;125(3):e508-12
pubmed: 20142295
Mol Ther. 2014 Dec;22(12):2118-2129
pubmed: 25027661
Obes Rev. 2020 Nov;21(11):e13128
pubmed: 32845580
Ann Rheum Dis. 2021 Oct;80(10):1306-1311
pubmed: 33762264